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Although compound heterozygosity, or the presence of two different mutant alleles of the same gene, is common in
human recessive disease, its potential to impact disease outcome has not been well documented. This is most likely
because of the inherent difficulty in distinguishing specific biallelic effects from differences in environment or genetic
background. We addressed the potential of different recessive alleles to contribute to the enigmatic pleiotropy
associated with XPD recessive disorders in compound heterozygous mouse models. Alterations in this essential
helicase, with functions in both DNA repair and basal transcription, result in diverse pathologies ranging from elevated
UV sensitivity and cancer predisposition to accelerated segmental progeria. We report a variety of biallelic effects on
organismal phenotype attributable to combinations of recessive Xpd alleles, including the following: (i) the ability of
homozygous lethal Xpd alleles to ameliorate a variety of disease symptoms when their essential basal transcription
function is supplied by a different disease-causing allele, (ii) differential developmental and tissue-specific functions of
distinct Xpd allele products, and (iii) interallelic complementation, a phenomenon rarely reported at clinically relevant
loci in mammals. Our data suggest a re-evaluation of the contribution of ‘‘null’’ alleles to XPD disorders and highlight
the potential of combinations of recessive alleles to affect both normal and pathological phenotypic plasticity in
mammals.
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Introduction
Interallelic complementation is deﬁned as the ability of two
differentially mutated alleles to function better together than
either can on its own. Despite its near universality in lower
organisms [1], its potential to contribute to clinical hetero-
geneity in human disease is seldom considered. Evidence of
interallelic complementation at clinically relevant loci is
limited to biochemical and cell-based studies of a handful of
metabolic disorders with defects in enzymes including
propinyl-CoA carboxylase [2], argininosuccinate lyase [3],
galactose-1-phosphate uridylyltransferase [4], and methylma-
lonyl CoA mutase [5].
Compound heterozygotes are individuals carrying two
different mutant alleles of the same gene. In the absence of
ad o m i n a n t( w i l d - t y p e[ w t ] )a llele, genetic interactions
between recessive alleles (referred to here as ‘‘biallelic’’
effects) could result in different phenotypic outcomes
including interallelic complementation. Although ameliora-
tion of disease symptoms by interallelic complementation
would create an ascertainment bias in the clinic, the lack of
evidence concerning interallelic complementation or other
biallelic effects in human disease is likely caused by the
difﬁculty in distinguishing such effects from environment
and genetic background.
XPD encodes one of the two helicase components of basal
transcription/DNA repair factor IIH (TFIIH), a ten-subunit,
multifunctional complex that is essential for multiple
processes, including basal transcription initiation and DNA
damage repair via the nucleotide excision repair (NER)
pathway [6,7]. Alterations in XPD resulting in defective TFIIH
function are associated with UV-sensitive, multisystem
disorders including xeroderma pigmentosum (XP), XP
combined with Cockayne syndrome (CS), and trichothiodys-
trophy (TTD) [8–10]. XP is marked by sun-induced pigmen-
tation anomalies and a greater than 1,000-fold elevation in
skin cancer risk. Severe cases can also present with growth
retardation and primary neurodegeneration [11]. CS and
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PLoS BIOLOGYTTD, on the other hand, are segmental progeroid disorders
characterised by progressive post-natal growth failure and
primary demyelination resulting in severe neurodysfunction,
but without a clear cancer predisposition [12–15]. Patients
with TTD additionally display hallmark sulphur-deﬁcient
brittle hair and nails and scaling skin [13], resulting from a
basal transcription defect in speciﬁc cell types [16,17]. A
related disorder with the cancer predisposition of XP
combined with the neurodevelopmental complications of
CS (XPCS), although rare, has also been described [18].
Many XPD mutations are associated with an exclusive
disease phenotype (e.g., XPD
R722W with TTD and XPD
R683W
with XP) and are thus viewed as causative of the correspond-
ing syndromes. Alleles not associated exclusively with one
disorder are considered ‘‘likely null’’ alleles [19,20]. Some of
these alleles fail to support viability in a haploid Schizosacchar-
omyces pombe yeast strain with a null mutation in the XPD
homologue rad15 and are thus considered devoid of
signiﬁcant biological activity [19]. This classiﬁcation of alleles
as either causative or null currently deﬁnes what we refer to
as a ‘‘monoallelic’’ paradigm of XPD disease. However, the
identiﬁcation in recent years of XP complementation group
D patients with atypical disease presentation, including
symptoms of both XP and TTD [8], casts doubt on the ability
of such a monoallelic paradigm to explain clinical hetero-
geneity in compound heterozygotes.
Previously, we generated a TTD mouse model (XPD
R722W)
that phenocopies the human syndrome [15,21]. Here we
report the generation of additional mutant Xpd alleles that fail
to support viability on their own but nevertheless ameliorate
TTD-associated premature segmental ageing, cutaneous fea-
tures, cellular DNA repair capacity, and UV survival when
present in a compound heterozygote state.
Results
Generation of Xpd Compound Heterozygotes
We generated an Xpd knock-in allele with a point mutation
encoding a single amino acid change (XPD
G602D) found in the
XPCS patient XPCS2 (Figure 1A–1C). mRNA expression from
the targeted allele could be detected in embryonic stem cells
by RT-PCR (Figure 1D), although expression was reduced
approximately 5-fold relative to wt mRNA transcript levels as
Figure 1. Targeting of the Mouse Xpd Gene
(A) Schematic representation of the genomic structure and partial
restriction map of the wt and targeted mouse Xpd loci. For the wt Xpd
allele, shaded boxes represent coding regions of exons 12 and 19–23; the
39UTR is represented by an open box. TGA indicates the translational
stop codon; PolyA indicates the polyadenylation signal. For the Xpd
TTD
targeted allele, the 194–base pair (bp) human XPD cDNA fragment fused
to exon 22 is indicated as a striped box including the TTD (R722W)
mutation indicated by a vertical arrow. Chicken b-globin exons 2 and 3
including the 39UTR are indicated as black boxes with corresponding
Roman numerals followed by the b-globin polyadenylation signal
(PolyA*). For the Xpd
XP and Xpd
XPCS targeted alleles, vertical arrows
indicate XPCS (G602D-encoding) and XP (R683W-encoding) mutations in
exons 19 and 22, respectively. The unique 39 probe located outside the
targeting construct is marked by a thick black line. Restriction sites: B,
BamHI; C, ClaI; E, EcoRI; H, HindIII; Hp, HpaI; Sf, SfiI.
(B) Southern blot analysis of EcoRI-digested genomic DNA from wt, Xpd
XPCS/wt,
and Xpd
XP/wt recombinant embryonic stem cell clones hybridised with
the 39 probe depicted in (A). The wt allele yields a 6.5-kilobase (kb)
fragment, whereas both targeted Xpd
XP and Xpd
XPCS alleles yield a 5.1-
kb fragment.
(C) Genotyping of wt and targeted alleles by PCR using primers F2, R1,
and mR as indicated in (A) yields fragments of 399 bp and 468 bp,
respectively.
(D) RT-PCR detection of mRNA expression originating from the targeted
XP and XPCS alleles in embryonic stem cell clones using primers F1
(hybridising outside the targeting construct) and mR as indicated in (A)
results in a 1,416-bp fragment.
(E) Northern blot analysis of total RNA isolated from testis of homozygous
wtandXpd
TTD/TTD, heterozygous Xpd
XPCS/wtandXpd
TTD/wt,andcompound
heterozygous Xpd
XPCS/TTD mice as indicated. Hybridisation with a 1.4-kb
mouseXpdcDNAprobedetectsmRNAsof4,3.3,and2.7kbfromwt,Xpd
XPCS,
and Xpd
TTD alleles, respectively. An ethidium bromide (EtBr)–stained gel
showing the amount of total RNA loaded is shown below.
DOI: 10.1371/journal.pbio.0040322.g001
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Compound Heterozygosity at the Xpd Locusdetermined by Northern blotting of RNA from the testis of
heterozygous animals (Figure 1E). Because patient XPCS2 was
a hemizygote with mutant XPD protein (XPD
G602D) expressed
f r o mas i n g l ea l l e l e ,t h ec o r r e s p o n d i n gm u t a t i o nw a s
expected to be viable in the homozygous state. However,
homozygous mutant mice were not observed, neither
amongst live births nor embryonic day 13.5 (E13.5) or E3.5
embryos (Table 1). The corresponding hypomorphic, mutant
allele was thus designated as homozygous lethal (XPCS).
Homozygous lethality of the XPCS allele is likely due to
reduced levels of expression of this essential protein as a
result of gene targeting (Figure 1A) rather than to the
mutation itself. Xpd ablation (Xpd
KO/KO) is similarly incompat-
ible with life beyond the earliest stages of embryogenesis [22].
Consistent with this interpretation, a different targeted Xpd
mutation encoding XPD
R683W, which is associated with XP in
the homozygous state in humans, was similarly underex-
pressed and lethal in the homozygous state (designated as XP
allele) (Figure 1A–1C; Table 1; unpublished data). Also, a
different targeting approach leading to the use of the native
39UTR and removal of the neo gene resulted in normalisation
of Xpd
XPCS mRNA levels and viable homozygous Xpd
XPCS/XPCS
(XPD
G602D/G602D) animals [23].
‘‘Null’’ Allele Can Alleviate Developmental Delay, Skin, and
Hair Features of TTD
To test the potential of a homozygous lethal ‘‘null’’ allele to
nevertheless contribute to organismal phenotype, we com-
bined an Xpd
XPCS allele with a viable Xpd
TTD allele by
crossing the corresponding heterozygous animals. Similar to
hemizygous TTD mice carrying one true Xpd knockout allele
(Xpd
TTD/KO), compound heterozygous Xpd
TTD/XPCS mice were
born at the expected Mendelian frequencies. Expression from
the Xpd
XPCS allele was also reduced in the testis of compound
heterozygous animals, whereas expression from the Xpd
TTD
allele was increased relative to wt by ;5-fold (Figure 1E).
Because of a lack of available antibodies and the inability to
distinguish amongst various mutant forms of XPD differing
only by single amino acid substitutions, we were unable to
ascertain the relative amount of XPD protein from the
different alleles.
Despite reduced levels of mRNA expression, the homozygous
lethal Xpd
XPCS allele ameliorated multiple Xpd
TTD-associated
disease symptoms in compound heterozygous Xpd
TTD/XPCS
animals including the hallmark brittle hair and cutaneous features
fully penetrant in homo- and hemizygous TTD mice (Figure 2A–
2C). In marked contrast to Xpd
TTD/TTD (and Xpd
TTD/KO) mice, which
display complete hair loss in the ﬁrst hair cycle and partial hair
loss in subsequent cycles throughout their lives [21], compound
heterozygous Xpd
TTD/XPCS mice displayed some hair loss only
during the ﬁrst hair cycle and only locally at the back (Figure 2A).
Scanning electron microscope analysis of Xpd
TTD/XPCS hair
revealed an almost normal appearance, with TTD-like features
such as broken hairs found only at very low frequency
(unpublished data). Amino acid analysis conﬁrmed that cysteine
levels in the hair of the Xpd
TTD/XPCS mice were signiﬁcantly higher
than in Xpd
TTD/TTD animals, but remained below the wt level
(Figure 2C). TTD hemizygotes (Xpd
TTD/KO) do not display
signiﬁcant differences in cutaneous features and longevity relative
to homozygous Xpd
TTD/TTD mice [21].
Other prominent TTD features in the epidermis, including
acanthosis (thickening of the layer of the nucleated cells),
hyperkeratosis (prominent thickening of the corniﬁed layer),
and pronounced granular layer and sebacious gland hyper-
plasia (causing greasy appearance of the hair), were absent in
the skin of Xpd
TTD/XPCS mice, as established by blind micro-
scopic examination of skin sections (Figure 2B). Furthermore,
anaemia and developmental delay present in patients with
TTD [24] and in Xpd
TTD/TTD mice [15] were both partially
rescued in compound heterozygous Xpd
TTD/XPCS mice (Figure
2D and 2E).
Rescue of Progeroid Features in TTD Mice by
Homozygous Lethal Xpd Alleles
Because patients with TTD, XPCS, and CS (but not XP) and
the corresponding mouse models share similar accelerated
progeroid symptoms [12,13,15,23], we next addressed ageing-
related parameters in compound heterozygous mice (Figure 3).
Whereas Xpd
TTD/TTD animals show reduced bone mineral density
as an indication of the early onset of osteoporosis before ;14
mo of age [15], tail vertebrae from compound heterozygous
Xpd
TTD/XPCS mice were comparable to wt even at 20 mo of age
(Figure 3B and 3C). Furthermore, whereas Xpd
TTD/TTD mice
developed kyphosis earlier than wt animals (onset ;3m ov e r s u s
12–20 mo), compound heterozygous Xpd
TTD/XPCS mice did not
(Figure 3B). Overall appearance and body weight curves revealed
that TTD-associated age-related premature cachexia and lack of
general ﬁtness were fully rescued in compound heterozygous
Xpd
TTD/XPCS mice (Figure 3A and 3D). Finally, the life span of
compound heterozygotes was extended relative to Xpd
TTD/TTD
mice (Table 2).
To determine whether the homozygous lethal Xpd
XPCS
allele was unique in its ability to ameliorate symptoms
associated with the Xpd
TTD allele, we generated compound
Table 1. Frequency of Xpd
XP/XP, Xpd
XPCS/XPCS, and Compound Heterozygous Xpd
XP/XPCS Embryos and Offspring
Genotype Age Analysed Expected
a (If Mendelian) Found
Xpd
XPCS /XPCS E3.5 26 6.5 0
E13.5 26 6.5 0
Newborn 129 32 0
Xpd
XP /XP E3.5 29 7 0
Newborn 144 36 0
Xpd
XP /XPCS Newborn 33 8 0
aDerived from Xpd
wt /XP, Xpdwt /XPCS, and Xpd
wt /XP to Xpd
wt /XPCS intercrosses.
DOI: 10.1371/journal.pbio.0040322.t001
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TTD/ XP mice by crossing the corresponding
heterozygous animals. Similar to the Xpd
XPCS allele, the
homozygous lethal Xpd
XP allele rescued cutaneous symptoms
including hair loss (except locally during the ﬁrst round;
unpublished data), reduced cysteine content (cysteine index
9.3 6 0.9 standard deviation [87% of wt], p ¼ 0.01 versus
TTD), ageing-associated premature cachexia (males and
females were 36.1 6 6.4 g [93% of wt] and 39.2 6 3.2 g
[116% of wt], respectively), and reduced life span (Table 2).
Taken together, these data indicate that two independent
alleles, which on their own are unable to support viability
(Table 1), were nonetheless able to ameliorate TTD-associ-
ated phenotypes in vivo (Table 2).
Molecular Mechanisms of Biallelic Effects
We next turned to UV-based cellular assays including
unscheduled DNA synthesis after UV irradiation (UV-
UDS), recovery of RNA synthesis after UV irradiation
(UV-RRS), and UV survival, which report on the NER
subpathways (global genome NER and transcription-
coupled NER) and total NER, respectively. In none of
these assays was the response to UV improved in
compound heterozygotes relative to TTD homozygotes
(Figure 4A–4C). However, unlike the in vivo TTD
phenotypes described above, in which Xpd
TTD/TTD and
Xpd
TTD/KO animals were indistinguishable, Xpd
TTD dosage
effects were observed in UV survival, UV-UDS, and UV-
RRS, indicating that cellular parameters as measured in
ﬁbroblasts here do not always correlate with the
phenotype at the level of the intact organism. Xpd
TTD/
KO hemizygous cells were thus used as the baseline on
which to compare the activity of compound heterozygous
cells. Relative to Xpd
TTD/KO hemizygote cells, UV survival
was improved by the homozygous lethal Xpd
XPCS allele in
Xpd
TTD/XPCS compound heterozygous cells and to a lesser
degree by the Xpd
XP allele (Figure 4A). Because of
Figure 2. Partial Rescue of TTD Cutaneous, Blood, and Developmental Phenotypes in Compound Heterozygous Xpd
TTD/XPCS Mice
(A) Photographs of 5-mo-old homozygous Xpd
TTD/TTD, compound heterozygous Xpd
TTD/XPCS, and wt mice. Insets: images of first-round hair loss.
(B) Histological analysis of the skin of Xpd
TTD/TTD,X p d
TTD/XPCS, and wt mice. TTD-associated acanthosis (thicker epidermis, indicated by
solid vertical line), pronounced granular layer (indicated by arrows), and sebacious gland hyperplasia (indicated by dotted vertical line)
were absent in the epidermis of Xpd
TTD/XPCS and wt mice. Magnification 4003.
(C) Cysteine content of hair from wt, Xpd
TTD/TTD, and Xpd
TTD/XPCS mice. The p-value indicates significant differences between mutants and wt, as well as
between Xpd
TTD/TTD and Xpd
TTD/XPCS mice. Error bars indicate standard error of the mean (SEM).
(D) Hematocrit values from blood of Xpd
TTD/TTD and Xpd
TTD/XPCS mice. The p-values indicate the significance of the difference relative to wt. Error bars
indicate SEM.
(E) Body weights of developing Xpd
TTD/TTD and Xpd
TTD/XPCS mice after weaning plotted as a percentage of the weight of age-matched control wt and
heterozygote (hz) littermates (set at 100%). Error bars indicate SEM.
DOI: 10.1371/journal.pbio.0040322.g002
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UV survival associated exclusively with the Xpd
XPCS or
Xpd
XP alleles. However, homozygous XPD
XP (XPD
R683W)
and hemizygous XPD
XPCS (XPD
G602D) human cells are
known to be highly sensitive to UV [19,25], as are cells
from a homozygous viable Xpd
XPCS/XPCS (XPD
G602D/G602D)
mouse model (Figure 4A, dotted line) [23]. Thus, the
survival of Xpd
TTD/XPCS (and Xpd
TTD/XP) cells likely
represents a level of UV resistance that neither mutant
allele can impart on its own (Table 2). Signiﬁcant effects
of compound heterozygosity on NER subpathways rela-
tive to Xpd
TTD/KO cells were observed in Xpd
TTD/XP cells
but only for UV-UDS activity. Finally, none of the
mutant TFIIH combinations (carrying alterations associ-
ated with TTD [XPD
R722W], XPCS [XPD
G602D], or XP
[XPD
R683W]) exhibited synergism in an in vitro NER
reaction reconstituted with different mutant TFIIH
complexes (Figure 4D). Taken together, these data are
consistent with interallelic complementation of UV
sensitivity in cells but underscore the lack of any
correlation between UV-related repair characteristics
and TTD progeroid phenotypes in animal models.
Next we asked whether the Xpd
XPCS and Xpd
XP alleles,
despite decreased mRNA levels, ameliorated TTD symptoms
by increasing overall TFIIH levels in compound heterozygous
Xpd
TTD/XPCS and Xpd
TTD/XP cells. Previously, using compa-
rative immunohistochemistry, we and others have shown an
up to 70% reduction of TFIIH levels in primary ﬁbroblasts
from patients with TTD compared with wt controls due to
reduced stability [16,17]. Despite overexpression of mRNA
from the Xpd
TTD allele relative to the wt allele (Figure 1E),
TFIIH protein levels were reduced by 50% in primary mouse
Figure 3. Rescue of TTD-Associated Segmental Progeroid Features in Compound Heterozygous Xpd
TTD/XPCS Mice
(A) Photographs of 20-mo-old wt, compound heterozygous Xpd
TTD/XPCS, and homozygous Xpd
TTD/TTD mice. Note the extreme cachexia (lack of
subcutaneousfat)intheXpd
TTD/TTDmouseandtheabsenceofthisphenotypeinwtandXpd
TTD/XPCSmice.
(B) Radiographs of 20-mo-old male wt, Xpd
TTD/XPCS, and Xpd
TTD/TTD mice. Ageing Xpd
TTD/TTD mice develop kyphosis (curvature of the spinal column) and
reduction of bone mineral density as shown in the 6–8 segment of the tail vertebrae counted from the pelvis (see close-up at right). Note the absence
of these features in the Xpd
TTD/XPCS mouse.
(C) Quantification of relative bone mineral density of tail vertebrae from 20-mo-old male wt (n¼3), Xpd
TTD/XPCS (n¼4), and Xpd
TTD/TTD (n¼3) mice. The
p-values indicate the significance of the difference relative to Xpd
TTD/TTD. Error bars indicate SEM.
(D) Body weight curves as a function of time. Note that the age-dependent cachexia observed in Xpd
TTD/TTD mice was rescued in both male
and female Xpd
TTD/XPCS mice. Significant differences between wt and Xpd
TTD/TTD but not between wt and Xpd
TTD/XPCS mice were observed at
9 and 18 mo of age as indicated by asterisks. Error bars indicate SEM.
DOI: 10.1371/journal.pbio.0040322.g003
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Compound Heterozygosity at the Xpd LocusXpd
TTD/TTD ﬁbroblasts (Figure 4E and 4F), thereby mimicking
the situation in human patients with TTD. In accordance with
the gene dosage, a further reduction of up to 70% of the wt
level was observed in hemizygous Xpd
TTD/KO cells. Consistent
with low mRNA expression levels, neither the Xpd
XPCS nor
the Xpd
XP allele was able to restore TFIIH abundance to wt
levels in Xpd
TTD compound heterozygote cells (Figure 4E and
4F). Thus, the improved UV survival observed in compound
heterozygote cells (Figure 4A) and likely the rescue of TTD
progeroid symptoms (Figure 3) were not due to normalisation
of TFIIH levels, suggesting a qualitative rather than a
quantitative effect on these phenotypes in vivo.
In contrast, the level of XPCS mRNA expression did affect
the ability of the encoded protein (XPD
G602D) to restore the
TTD hair phenotype to normal. Notably, Xpd
TTD/XPCS
animals had a partial TTD hair phenotype, correlating with
low levels of Xpd
XPCS expression, whereas Xpd
TTD/XPCS
animals had wt hair, correlating with normal expression
levels from the viable Xpd
XPCS allele (Table 2 and unpublished
data). Thus, the range of expression levels from these two
mutant alleles affected their ability to complement some
phenotypes (hair). An overview of the functional relation-
ships between Xpd alleles, phenotypes, and the presumed
underlying TFIIH function in mice and cells is presented in
Table 2.
Discussion
Dissection of Biallelic Effects from other Determinants of
Phenotype
Although phenotypic consequences, referred to here as
biallelic effects, resulting from two different mutant alleles in
compound heterozygote patients have been postulated, such
effects have historically been difﬁcult to distinguish from the
inﬂuence of environment and genetic background. We used a
genetically deﬁned mammalian model system under con-
trolled environmental conditions to reveal phenotypic effects
attributable speciﬁcally to combinations of differentially
mutated Xpd alleles.
The observed biallelic effects were of three general types.
In the ﬁrst, the allele associated in a homozygous state with
a phenotype closer to wt singularly determined the
Table 2. Pleiotropic Xpd Biallelic Effects in Mice and Cells
Presumed TFIIH Function Phenotype Genotype
TTD/TTD TTD/KO XPCS/XPCS
a KO/KO and
XPCS/XPCS
TTD/XPCS
(Allelic Relation)
b
General transcription
defect
Embryonic lethality Absent Absent Absent Present Absent
(TTD dominant)
c
Transcription defect
of hair/skin/blood
Fragile hair with
reduced cysteine
content
Present Present Absent n.a Intermediate
(XPCS dominant)
c,d,e
Acanthosis, hyperkeratosis,
sebacious gland hyperplasia
Present Present Absent n.a. Absent
(XPCS dominant)
c
Anaemia Present n.d. Absent n.a. Intermediate
(XPCS dominant)
c
UV-damage repair Cellular UV hypersensitivity Mild Moderate
d Severe n.a. Mild (interallelic comp)
Transcription-coupled NER UV-RRS ;30% ;15% ,5% n.a. ;25% (TTD dominant)
c
Global genome NER UV-UDS ;50% ;25% ;30% n.a. ;25%
f
Transcription-coupled
DNA repair
Developmental delay Moderate Moderate Mild n.a Mild
(XPCS dominant)
c
Cachexia Severe Severe Mild n.a Absent (interallelic comp)
e
Premature loss of bone
mineral density
Severe n.d. n.d. n.a. Absent
(XPCS dominant)
c
Life span
g Reduced Reduced Reduced n.a. Normal (interallelic comp)
Life span in Xpa
 / 
background
h
;3 wk n.d. ;3 wk n.a. ;6m o(interallelic comp)
aFor a complete description of Xpd
XPCS/XPCS homozygous mice, please see [23].
bAllelic relationships in Xpd compound heterozygotes are colour-coded as follows: blue, XPCS or XPCS allele dominant over TTD allele; green, TTD allele dominant over XPCS or XPCS
allele; red, interallelic complementation (comp).
cDominant is defined as closer to wt function in comparison with the other mutant allele present in the compound heterozygote, with respect to a given phenotype/function.
dXPD protein expression level–dependent.
eAlso demonstrated in Xpd
TTD/XP compound heterozygous animals.
fBecause in XPCS cells the 30% UV-UDS is not associated with actual lesion removal, whereas in TTD it is [23], the allelic relationship between the alleles with respect to UV-UDS is
unknown.
gIn the 129Ola/C57BL6 mixed genetic background used in a previous study [15], the average life span of Xpd
TTD/TTD mice was approximately 12 mo. Nevertheless, three out of six Xpd
TTD/TTD
mice included in this study lived until 19–20 mo, although their overall appearance was poor at the time they were killed (Figure 3A). Xpd
TTD/XPCS mice (n¼8) reached the age of 19–20
mo and were in a good condition at the time they were killed (Figure 3A). Two Xpd
TTD/XPCS animals not killed died at 24 and 26 mo of age, which is in the wt range. Similar condition and
life span extension were observed in Xpd
TTD/XP mice (n¼6) killed at the age of 19–20 mo for analysis. Xpd
XPCS/XPCS mice had a mean life span of ;18 mo that was significantly shorter than
controls (;21 mo, log rank p ¼ 0.001; [23]).
hIn the absence of XPA, another essential NER protein, DNA repair capacity is further reduced, resulting in accelerated TTD- and XPCS-like features and a reduced life span of ;3w ki n
Xpd
XPCS/XPCS/Xpa
 /  and Xpd
TTD/TTD/Xpa
 /  mice. Xpd
TTD/XPCS/Xpa
 /  animals survived significantly longer (van de Ven HWM, Andressoo JO, Jong W, Holcomb VB, de Zeeuw CI, et al.,
unpublished data).
n.a., not applicable; n.d., not determined.
DOI: 10.1371/journal.pbio.0040322.t002
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Compound Heterozygosity at the Xpd Locusphenotypic outcome, a phenomenon widely known in
human recessive disease. Because these Xpd alleles func-
tioned at or near wt levels with respect to a particular
function, we call these effects ‘‘dominant’’. Such alleles can
also be referred to as ‘‘separation of function’’ alleles,
because they allow dissection of the roles of multifunctional
proteins in speciﬁc phenotypes.
Secondly, highlighting the potential relevance of current
ﬁndings to all diploid organisms including humans was the
observation that in one compound heterozygous animal, the
Xpd allelic relationship could shift from Adominantjarecessive to
Arecessivejadominant with respect to different phenotypes in a
time-dependent and tissue-speciﬁc manner (see below and
Table 2).
In the third type of biallelic effect, known as interallelic
complementation, two mutant alleles produced a phenotype
closer to wt than either could alone in a homo- or hemizygous
state. As summarised in Table 2, examples of all types of
biallelic effects were observed in a variety of Xpd-associated
phenotypes, ranging from brittle hair to segmental progeria.
Figure 4. TFIIH Functions and Mechanisms of XPD-Associated Disease Pleiotropy
(A) Cellular survival after UV irradiation. Rescue of hemizygous Xpd
TTD/KO survival by Xpd
XPCS and Xpd
XP alleles is illustrated by arrows marked A and B,
respectively. UV survival of homozygous Xpd
XPCS/XPCS cells (asterisk) from the normally expressed viable allele (Xpd
XPCS) is depicted by a dotted line.
Survival curves represent an average of four independent experiments; 1–2 cell lines per genotype were included in each experiment. Error bars
indicate SEM between experiments.
(B) UV-UDS, a measure of global genome repair. Number of experiments: n ¼ 15 (Xpd
TTD/TTD), n ¼ 6 (Xpd
TTD/KO), n ¼ 4 (Xpd
TTD/XPCS), n ¼ 2
(Xpd
TTD/XP); 1–2 cell lines per genotype were included in each experiment. The asterisk indicates significant difference with Xpd
TTD/TTD; crosses
indicate significant differences with Xpd
TTD/KO.
(C) UV-RRS,ameasureoftranscription-coupledrepairofUV-inducedlesions.Numberofexperiments:n¼7(Xpd
TTD/TTD),n¼2(Xpd
TTD/KO),n¼4(Xpd
TTD/XPCS),
n ¼ 2 (Xpd
TTD/XP); 1–2 cell lines per genotype were included in each experiment.
(D) Incision/excision activity of combinations of altered TFIIH complexes in a reconstituted NER reaction. Equal amounts of single or mixed populations
of recombinant TFIIHs (containing XPD, XPB, p62, p52, His-p44, Flag-p34, cdk7, cyclin H, Mat1, and p8) were mixed with recombinant XPG, XPF/ERCC1,
XPC/hHR23B, RPA, and a radiolabelled synthetic NER substrate. The excision products (26–34 nucleotides in length) were visualised at nucleotide
resolution on a denaturing polyacrylamide gel as indicated . Note the weak activity corresponding to each single and combined TFIIH complex (lanes 3–
8) relative to the wt (lane 1) and negative controls (lane 2).
(E) Xpd dose-dependent reduction of TFIIH in homozygous Xpd
TTD/TTD, hemizygous Xpd
TTD/KO, and compound heterozygous Xpd
TTD/XPCS and Xpd
TTD/XP
cells by comparative immunofluorescence of the p62 subunit of TFIIH. Roman numerals represent different microscopic slides and Arabic numerals
different cell lines labelled as follows: (I) wt cells (1) labelled with 2-lm beads, Xpd
TTD/TTD cells (2) with 0.79-lm beads, and Xpd
TTD/KO cells (3) with no
beads; (II) wt cells (1) labelled with 0.79-lm beads and Xpd
TTD/XPCS cells (4) with no beads; and (III) wt cells (1) labelled with 0.79-lm beads and Xpd
TTD/XP
cells (5) with no beads.
(F) Quantification of immunofluorescent signal from at least 50 nuclei per cell line and 2–6 experiments per genotype. Bars representing cells analysed
on the same microscopic slide are depicted side by side, with wt set at 100%. The p-value indicates minimum significant difference between wt and the
indicated cell lines analysed on the same microscopic slide within one experiment.
DOI: 10.1371/journal.pbio.0040322.g004
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Disease Pleiotropy
We observed differences in the ability of Xpd
TTD versus
homozygous lethal Xpd
XPCS and Xpd
XP alleles to function in
two transcription-related phenotypes separated in the
organism by both time and space: embryonic lethality and
terminal differentiation of enucleating skin and blood cells.
The preblastocyst-stage homozygous lethality shared by the
Xpd
KO, Xpd
XPCS, and Xpd
XP alleles most likely reﬂects a
defect in basal transcription that is incompatible with life.
In Xpd
TTD/XPCS and Xpd
TTD/XP compound heterozygous
mice, embryonic lethality was fully rescued by the Xpd
TTD
allele. Because embryonic lethality was also fully rescued in
Xpd
TTD/KO hemizygous mice, the Xpd
TTD allele can be
considered as wt and thus dominant to each of the
homozygous lethal alleles (Xpd
KO, Xpd
XPCS, and Xpd
XP) with
respect to this particular phenotype (Table 2).
TTD-speciﬁc cutaneous and anaemic features, on the other
hand, are thought to result from a speciﬁc kind of transcrip-
tional insufﬁciency caused by depletion of unstable TFIIH
during the terminal differentiation of skin, hair-shaft, and
blood cells [16,24]. In compound heterozygous mice, both
homozygous lethal Xpd
XPCS and Xpd
XP alleles were able to
alleviate Xpd
TTD-speciﬁc cutaneous and anaemic features and
can thus be deﬁned as dominant over the Xpd
TTD allele with
respect to these phenotypes. We conclude that the defects
leading to embryonic lethality and aberrant terminal differ-
entiation of the skin, hair, and blood represent two
qualitatively and/or quantitatively different transcriptional
deﬁciencies. During early embryonic development, Xpd
TTD is
dominant over the Xpd
XPCS and Xpd
XP alleles, whereas later
in the ontogenesis of skin, hair-shaft, and blood cells, the
situation is reversed.
In its role in the repair of UV photolesions, the Xpd
XPCS
allele imparted a clear UV survival beneﬁt over a single Xpd
TTD
allele or two Xpd
XPCS alleles independent of expression levels,
which is consistent with interallelic complementation. How-
ever,theobservationthatnoothercellularorbiochemicalUV-
related parameters were improved in Xpd
TTD/XPCS argues
againstcomplementationofthisrepairactivityintherescueof
TTD progeroid symptoms in vivo.
Interallelic Complementation and XPD Function
What does interallelic complementation tell us about the
mechanism of XPD function? Interallelic complementation is
most often observed in multimeric proteins with multiple
functional domains. Unfortunately, the structure–function
relationship between disease-causing mutations and XPD
functional domains, including detailed structural information
on XPD or even its stoichiometry within TFIIH, remains
unknown.However,basedontheabilityofcellextractsthatare
defective in two different TFIIH components (XPD and XPB)
to complement NER activity in vitro [26], it is likely that TFIIH
(oritscomponents)caneithermultimeriseorexchangeatleast
during the NER reaction. Furthermore, XPD is known to be a
‘‘loosely bound’’ subunit of TFIIH [27]. We thus envisage the
molecular mechanism of interallelic complementation to
involve the exchange of XPD molecules within the TFIIH
complex or turnover of TFIIH complexes containing different
XPD molecules at the siteof DNA damageduring thecourse of
the global genome as well as transcription-coupled repair of
either UV-induced or endogenous DNA damage.
A Biallelic Paradigm for XPD Disorders
Recently, proteins originating from presumed null alleles
were biochemically characterised as inactive in basal tran-
scription [27], providing an explanation as to why these alleles
failedtorescuelethalityinhaploidS.pombewithanullmutation
intheXPDhomologuerad15[19].Ourdatasuggestthatcertain
presumednullalleles,althoughunableontheirowntosupport
basal transcription, may in fact have a substantial impact on
disease outcome in compound heterozygous humans, as they
do in mouse models.
Clinical evidence in support of this hypothesis comes from
a number of XP complementation group D patients that do
Figure 5. Genotype–Phenotype Relationships in XPD Disorders
According to the current monoallelic hypothesis, phenotype is
determined solely by the causative allele product. If a second, different
allele is present, it is considered a functional null. There is a lack of any
correlation between the site of the XPD mutation and the resulting
disorder. We propose a biallelic hypothesis for compound heterozygotes
in which both alleles can contribute to the phenotype. Examples of
compound heterozygous patients in which a second, presumed null
allele is likely to contribute to disease outcome are provided above in
comparison to corresponding homo- or hemizygous patients with the
same causative allele. Numbers in the schematic of the protein indicate
the helicase domains.
DOI: 10.1371/journal.pbio.0040322.g005
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Compound Heterozygosity at the Xpd Locusnot ﬁt within the framework of the current monoallelic
paradigm of XPD disorders (Figure 5). In contrast to two
hemizygous XPD
XPCS patients carrying the XPD
G47R-o r
XPD
R666W-encoding alleles who died of the disease before
2 y of age, two compound heterozygous XPD
XPCS patients
carrying the same XPD
G47R- or XPD
R666W-encoding alleles in
addition to the presumed null XPD
L461Vþdel716 730 both had
considerably milder disease symptoms and survived more
than ten times longer (A. Lehmann, personal communica-
tion) (Figure 5). Compound heterozygosity is also associated
with the recently reported combination XP and TTD
(XPTTD) syndrome [8]. Similar to the Xpd
TTD/XPCS and
Xpd
TTD/XP mice described here, both patients with XPTTD
described so far had intermediate hair cysteine values.
Furthermore, XPTTD patient XP38BR carried a ‘‘causative’’
TTD mutation in one allele and a novel point mutation
encoding XPD
L485P in the other. Although the XPD
L485P-
encoding allele fails to complement viability in the haploid S.
pombe rad15 deletion strain and is thus interpretable as a null
allele [8], we nonetheless suggest that the combined XPTTD
phenotype in this patient involves phenotypic contributions
from both alleles. Taken together, these data suggest a shift to
a biallelic paradigm for compound heterozygous patients in
XP complementation group D.
Potential of Combined Recessive Alleles to Affect
Phenotypic Diversity in Mammals
In humans, the clinical relevance of biallelic effects such as
interallelic complementation remains unknown. Although
interallelic complementation between two endogenous mu-
tant alleles has been described in cells from a compound
heterozygous patient with methylmalonic acidaemia, no
observable effects on disease outcome were noted in the
patient [28]. Thus, to the best of our knowledge, the
amelioration of progeroid features observed here is the ﬁrst
in vivo demonstration in compound heterozygous animals of
interallelic complementation relevant to a human disease.
Keeping in mind that the ;1,200 alleles known to exist for the
CTRF gene implicated in the common autosomal recessive
disorder cystic ﬁbrosis alone [29] can theoretically result in
;700,000 different allelic combinations, the potential number
of allelic combinations of different recessive mutations and
single nucleotide polymorphisms genome-wide is currently
incalculable. We suggest biallelic effects as a previously
underestimated yet important variable in considering geno-
type–phenotype relationships from autosomal recessive dis-
ease to normal phenotypic diversity in mammals. Extension of
the above concept implies that recessive mutations can enter
evolutionary selection in F1 provided that the second allele
carries a different recessive alteration. Finally, our data
highlight the potential of clinically relevant alleles previously
designated as null, with little or no detectable expression or
activity, to nonetheless contribute to phenotype.
Materials and Methods
Derivation and analysis of mutant mice. Generation of Xpd
TTD
(XPD
R722W) and Xpd
TTD/KO mice has been described previously
[21,22]. A detailed description of the generation of targeting
constructs for Xpd
XPCS and Xpd
XP alleles carrying mutations
encoding the G602D and R683W alterations will be provided upon
request. Chimeric mice and mouse embryonic ﬁbroblasts were
generated according to standard procedures. Haematoxylin and
eosin staining was performed according to standard procedures.
Amino acid analysis was conducted as described in [21]. Blood values
were analysed using Animal Blood Counter Vet (ABX Diagnostix,
Montpellier, France). Radiographs were taken, and relative bone
mineral density was calculated as described in [15]. Mice used in this
study were in a 129Ola/C57BL6 mixed background unless noted
differently. All experiments involving mice were judged and
approved by the national committee for genetic identiﬁcation of
organisms and the animal ethical committee, and were conducted
according to national and international guidelines.
UV sensitivity, UV-UDS, UV-RRS, and TFIIH incision/excision
activity. UV survival, UV-UDS, and UV-RRS assays were performed
as described previously [21,30]. For UV-RRS, average values from
the representative experiment containing two wt, three Xpd
TTD/TTD,
two Xpd
TTD/XPCS, and one Xpd
TTD/XP cell line are presented. The
;48% UV-UDS value presented in this study for Xpd
TTD/TTD cells
differs from our previously published data of 25% UV-UDS [21],
possibly because of the high variability intrinsic to the assay or
routine variations in the cell culture conditions. For the incision/
excision activity assay, recombinant TFIIH was prepared and
assayed as described previously [27].
Comparative immunoﬂuorescence. Latex bead labelling and
comparative immunoﬂuorescence analysis of the p62 subunit of
the TFIIH was performed as described previously [16,17] using
primary mouse embryonic ﬁbroblasts at passages 2–5. Two or
more cell lines per genotype (except for the Xpd
TTD/XP cells, in
which only one cell line was used in repeated experiments) were
used, and experiments were repeated 2–6 times per genotype.
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